AIDSWEEKLY Plus; Monday, March 13, 2000
Prepared by AIDS Weekly editors from staff and other reports

Researcher P.G.A. Cornelisse and colleagues from the University of British Columbia sought to characterize the effect of zidovudine therapy on AIDS dementia complex (dementia) free survival among HIV infected men and women in a population-based cohort with free access to antiretroviral therapy in the province of British Columbia ("The impact of zidovudine on dementia-free survival in a population of HIV positive men and women on antiretroviral therapy," Int J STD AIDS 2000 Jan;11(1):52-6.

Time to diagnosis of dementia among individuals was examined on the basis of zidovudine duration, CD4⁺ cell count at first treatment, gender, and transmission group [men having sex with men (MSM), intravenous drug users (IDU), heterosexuals].

The researchers restricted the analysis to patients with CD4⁺ cells counts within 12 months prior to treatment start date. Among 641 participants eligible for analysis, median duration of follow-up was 3.6 years, under which 86 (9.3%) events of dementia occurred.

Participants were less likely to develop dementia with: increased zidovudine exposure (OR=0.26, 95% CI: 0.14-0.49), at least 260 CD4⁺ cells/mm³ (median) (OR=0.52, 95% CI: 0.34-0.78), and MSM risk group (OR=0.57, 95% CI: 0.35-0.94). Those infected through heterosexual contact had an increased risk (RR=2.04, 95% CI: 1.02-4.07).

Using Cox's proportional hazards model, controlling for CD4⁺ cell count at treatment start date, independent predictors of dementia-free survival were: duration of zidovudine (OR=0.28, 95% CI: 0.15-0.52) and MSM transmission group (OR=0.61, 95% CI: 0.37-1.00).

"In this observational treatment cohort, factors associated with dementia-free survival include duration of zidovudine (AZT) therapy and MSM transmission group," Cornelisse et al. wrote. "It is not clear from these data whether the AZT protective effect is exclusive to this agent or whether other therapies might offer a similar protective effect."

A search of www.NewsRx.com found 11 articles dealing with zidovudine and dementia.

The corresponding author for this study is R.S. Hogg, University of British Columbia, St. Paul's Hospital, BC Ctr Excellence HIV AIDS, Division of Epidemiology & Population Health, Faculty of Medicine, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.

Key points reported in this study are:

• Zidovudine therapy for extended periods was associated with dementia-free survival of HIV infected patients
  
  
• Independent predictors of dementia-free survival were duration of zidovudine and MSM transmission group
  
  
• Further studies are needed to determine whether other therapies have a similar protective effect
  

This article was prepared by AIDS Weekly editors from staff and other reports.

000313
AW000305

Copyright © 2000 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.